背景:巨噬细胞胞葬作用障碍引起的局部和系统炎症损害与多种肥胖相关代谢性疾病有关,且以胞葬作用为靶向的化合物表现出良好的治疗效果。目的:通过综述肥胖对巨噬细胞胞葬作用各个阶段的影响结果分析肥胖抑制胞葬作用的关键机制,总结以...背景:巨噬细胞胞葬作用障碍引起的局部和系统炎症损害与多种肥胖相关代谢性疾病有关,且以胞葬作用为靶向的化合物表现出良好的治疗效果。目的:通过综述肥胖对巨噬细胞胞葬作用各个阶段的影响结果分析肥胖抑制胞葬作用的关键机制,总结以胞葬作用为靶向的化合物治疗代谢性疾病的研究现状,以进一步阐明胞葬作用及其与肥胖相关代谢性疾病的关系,为疾病防治策略提供新思路。方法:以“efferocytosis,metabolism,obesity,obese,atherosclerosis,non-alcoholic steatohepatitis,neurodegeneration,tumor,osteoarthritis,diabetes,compound,medicine,treatment”为英文检索词在PubMed和Web of Science数据库检索英文文献,以“胞葬作用”为中文检索词,在中国知网、万方和维普数据库检索中文文献。经严格筛选最终纳入99篇文献进入综述分析。结果与结论:①参与巨噬细胞胞葬作用“寻我”“食我”过程的因子中含有大量凋亡细胞源性因子,因此“寻我”“食我”过程主要受凋亡细胞调控;参与骨架重组和消化过程的胞葬因子主要来源于巨噬细胞,对巨噬细胞胞葬作用活性具有决定性作用。此结果提示,“寻我”“食我”过程的因子表达水平主要反映细胞凋亡情况,在评价巨噬细胞胞葬作用活性时,选择骨架重组和消化阶段的胞葬因子的表达更具科学性。②肥胖抑制巨噬细胞胞葬作用,但肥胖对多数“寻我”“食我”因子及骨架重组因子具有应激性激活作用,对多数消化因子具有抑制作用。此结果进一步说明,消化阶段对胞葬作用活性的决定性意义,并提示部分研究以“寻我”“食我”胞葬因子表达增加作为胞葬作用增强的依据不可靠;且提示未来在探讨以巨噬细胞胞葬作用为靶向的干预策略时,靶向消化阶段胞葬因子可能更有效。③巨噬细胞胞葬作用激活物对多种代谢性疾病治疗有效,但肿瘤组织巨�展开更多
Atherosclerosis(AS)is characterized by impairment and apoptosis of endothelial cells,continuous systemic and focal inflammation and dysfunction of vascular smooth muscle cells,which is documented as the traditional ce...Atherosclerosis(AS)is characterized by impairment and apoptosis of endothelial cells,continuous systemic and focal inflammation and dysfunction of vascular smooth muscle cells,which is documented as the traditional cellular paradigm.However,the mechanisms appear much more complicated than we thought since a bulk of studies on efferocytosis,transdifferentiation and novel cell death forms such as ferroptosis,pyroptosis,and extracellular trap were reported.Discovery of novel pathological cellular landscapes provides a large number of therapeutic targets.On the other side,the unsatisfactory therapeutic effects of current treatment with lipid-lowering drugs as the cornerstone also restricts the efforts to reduce global AS burden.Stem cell-or nanoparticle-based strategies spurred a lot of attention due to the attractive therapeutic effects and minimized adverse effects.Given the complexity of pathological changes of AS,attempts to develop an almighty medicine based on single mechanisms could be theoretically challenging.In this review,the top stories in the cellular landscapes during the initiation and progression of AS and the therapies were summarized in an integrated perspective to facilitate efforts to develop a multi-targets strategy and fill the gap between mechanism research and clinical translation.The future challenges and improvements were also discussed.展开更多
Immunogenic dying tumor cells hold promising prospects as cancer vaccines to activate systemic immunity against both primary and metastatic tumors.Especially,X-ray-induced dying tumor cells are rich in highly immunoge...Immunogenic dying tumor cells hold promising prospects as cancer vaccines to activate systemic immunity against both primary and metastatic tumors.Especially,X-ray-induced dying tumor cells are rich in highly immunogenic tumor-associated antigens and self-generated dsDNA as potent adjuvants.However,we found that the X-ray induction process can result in the excessive exposure of phosphatidylserine in cancer vaccines,which can specifically bind with the MerTK receptor on macrophages,acting as a“checkpoint”to facilitate immune silence in the tumor microenvironment.Therefore,we developed a novel strategy combining X-ray-induced cancer vaccines with UNC2250,a macrophage MerTK“checkpoint inhibitor,”for treating peritoneal carcinomatosis in colon cancer.By incorporating UNC2250 into the treatment regimen,immunosuppressive efferocytosis of macrophages,which relies on MerTK-directed recognition of phosphatidylserine on vaccines,was effectively blocked.Consequently,the immune analysis revealed that this combination strategy promoted the maturation of dendritic cells and M1-like repolarization of macrophages,thereby simultaneously eliciting robust adaptive and innate immunity.This innovative approach utilizing X-ray-induced vaccines combined with a checkpoint inhibitor may provide valuable insights for developing effective cancer vaccines and immunotherapies targeting colon cancer.展开更多
文摘背景:巨噬细胞胞葬作用障碍引起的局部和系统炎症损害与多种肥胖相关代谢性疾病有关,且以胞葬作用为靶向的化合物表现出良好的治疗效果。目的:通过综述肥胖对巨噬细胞胞葬作用各个阶段的影响结果分析肥胖抑制胞葬作用的关键机制,总结以胞葬作用为靶向的化合物治疗代谢性疾病的研究现状,以进一步阐明胞葬作用及其与肥胖相关代谢性疾病的关系,为疾病防治策略提供新思路。方法:以“efferocytosis,metabolism,obesity,obese,atherosclerosis,non-alcoholic steatohepatitis,neurodegeneration,tumor,osteoarthritis,diabetes,compound,medicine,treatment”为英文检索词在PubMed和Web of Science数据库检索英文文献,以“胞葬作用”为中文检索词,在中国知网、万方和维普数据库检索中文文献。经严格筛选最终纳入99篇文献进入综述分析。结果与结论:①参与巨噬细胞胞葬作用“寻我”“食我”过程的因子中含有大量凋亡细胞源性因子,因此“寻我”“食我”过程主要受凋亡细胞调控;参与骨架重组和消化过程的胞葬因子主要来源于巨噬细胞,对巨噬细胞胞葬作用活性具有决定性作用。此结果提示,“寻我”“食我”过程的因子表达水平主要反映细胞凋亡情况,在评价巨噬细胞胞葬作用活性时,选择骨架重组和消化阶段的胞葬因子的表达更具科学性。②肥胖抑制巨噬细胞胞葬作用,但肥胖对多数“寻我”“食我”因子及骨架重组因子具有应激性激活作用,对多数消化因子具有抑制作用。此结果进一步说明,消化阶段对胞葬作用活性的决定性意义,并提示部分研究以“寻我”“食我”胞葬因子表达增加作为胞葬作用增强的依据不可靠;且提示未来在探讨以巨噬细胞胞葬作用为靶向的干预策略时,靶向消化阶段胞葬因子可能更有效。③巨噬细胞胞葬作用激活物对多种代谢性疾病治疗有效,但肿瘤组织巨�
基金supported by the National Natural Science Foundation of China(No.81573957,No.81874461 and No.82070307).
文摘Atherosclerosis(AS)is characterized by impairment and apoptosis of endothelial cells,continuous systemic and focal inflammation and dysfunction of vascular smooth muscle cells,which is documented as the traditional cellular paradigm.However,the mechanisms appear much more complicated than we thought since a bulk of studies on efferocytosis,transdifferentiation and novel cell death forms such as ferroptosis,pyroptosis,and extracellular trap were reported.Discovery of novel pathological cellular landscapes provides a large number of therapeutic targets.On the other side,the unsatisfactory therapeutic effects of current treatment with lipid-lowering drugs as the cornerstone also restricts the efforts to reduce global AS burden.Stem cell-or nanoparticle-based strategies spurred a lot of attention due to the attractive therapeutic effects and minimized adverse effects.Given the complexity of pathological changes of AS,attempts to develop an almighty medicine based on single mechanisms could be theoretically challenging.In this review,the top stories in the cellular landscapes during the initiation and progression of AS and the therapies were summarized in an integrated perspective to facilitate efforts to develop a multi-targets strategy and fill the gap between mechanism research and clinical translation.The future challenges and improvements were also discussed.
基金This research was supported by the National Natural Science Foundation of China(No.82104098,China)the Program for HUST Academic Frontier Youth Team(No.2018QYTD13,China)+1 种基金Wuhan Science and Technology Plan(2022023702025187,China)Natural Science Foundation of Hubei Province(2023AFD152,China).
文摘Immunogenic dying tumor cells hold promising prospects as cancer vaccines to activate systemic immunity against both primary and metastatic tumors.Especially,X-ray-induced dying tumor cells are rich in highly immunogenic tumor-associated antigens and self-generated dsDNA as potent adjuvants.However,we found that the X-ray induction process can result in the excessive exposure of phosphatidylserine in cancer vaccines,which can specifically bind with the MerTK receptor on macrophages,acting as a“checkpoint”to facilitate immune silence in the tumor microenvironment.Therefore,we developed a novel strategy combining X-ray-induced cancer vaccines with UNC2250,a macrophage MerTK“checkpoint inhibitor,”for treating peritoneal carcinomatosis in colon cancer.By incorporating UNC2250 into the treatment regimen,immunosuppressive efferocytosis of macrophages,which relies on MerTK-directed recognition of phosphatidylserine on vaccines,was effectively blocked.Consequently,the immune analysis revealed that this combination strategy promoted the maturation of dendritic cells and M1-like repolarization of macrophages,thereby simultaneously eliciting robust adaptive and innate immunity.This innovative approach utilizing X-ray-induced vaccines combined with a checkpoint inhibitor may provide valuable insights for developing effective cancer vaccines and immunotherapies targeting colon cancer.
